You are here
Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab
Janjigian YY, Riches JC, Ku GY, Imtiaz T, Capanu M, Chou JF, et al.Journal of Clinical Oncology 2015;33(3 suppl):63
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al.Lancet Oncol. 2017 May;18(5):640-653.
Commentary by Prof Lordick and Dr Elizabeth Smyth:
Trastuzumab plus chemotherapy is the standard of care for first-line treatment...
Naureen StarlingNew ESMO clinical practice guidelines on gastric cancer were published in 2016. Dr Starling takes the audience on a journey that addresses: the advances in chemotherapy treatments over the past 2 decades, the impact of targeted therapies, and the relatively new area of checkpoint inhibitors. She summarises many of the negative clinical trial results and highlights emerging areas of clinical research in advanced/metastatic gastric and gastroesophageal junction (GEJ) cancer.
Grillo F, Fassan M, Sarocchi F, Fiocca R, Mastracci L.World J Gastroenterol 2016 Jul 14;22(26):5879-87.
EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
Birkman E-M, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén OBMC Cancer. 2016; 16: 406.
A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
Kataoka H, Mori Y, Shimura T, Nishie H, Natsume M, Mochizuki H, et al.Cancer Chemother Pharmacol. 2016 Mar 22. [Epub ahead of print]
Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
Sook Ryun Park, Young Soo Park, Min-Hee Ryu, Baek-Yeol Ryoo, Chang Gok Woo, Hwoon-Yong Jung, Jeong Hoon Lee, Gin Hyug Lee, Yoon-Koo Kang
European Journal of Cancer, January 2016, Pages 42 - 50
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al.BMC Cancer. 2016 Feb 8;16(1):68.
Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer
Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, et al.Gastric Cancer. 2016 Feb 13. [Epub ahead of print]
Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK)
Saito M, Yamashita K, Arimura Y, Kaneto H, Okuda H, Nojima M, et al.Acta Oncol. 2016 Jan 12:1-9. [Epub ahead of print]